Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:EW
- CUSIP: 28176E10
- Web: www.edwards.com
Capitalization:- Market Cap: $24.97493 billion
- Outstanding Shares: 209,802,000
Average Prices:- 50 Day Moving Avg: $117.42
- 200 Day Moving Avg: $103.28
- 52 Week Range: $81.12 - $121.75
P/E:- Trailing P/E Ratio: 39.70
- Foreward P/E Ratio: 30.08
- P/E Growth: 2.21
Sales & Book Value:- Annual Revenue: $3.15 billion
- Price / Sales: 7.95
- Book Value: $13.04 per share
- Price / Book: 9.16
Profitability:- EBIDTA: $1.01 billion
- Net Margins: 20.85%
- Return on Equity: 25.80%
- Return on Assets: 15.36%
Debt:- Debt-to-Equity Ratio: 0.31%
- Current Ratio: 3.45%
- Quick Ratio: 2.71%
Misc:- Average Volume: 1.34 million shs.
- Beta: 0.64
- Short Ratio: 1.85
Frequently Asked Questions for Edwards Lifesciences Corporation (NYSE:EW)
What is Edwards Lifesciences Corporation's stock symbol?
Edwards Lifesciences Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."
When did Edwards Lifesciences Corporation's stock split? How did Edwards Lifesciences Corporation's stock split work?
Edwards Lifesciences Corporation's stock split on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were payable to shareholders after the market closes on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences Corporation stock prior to the split would have 200 shares after the split.
How were Edwards Lifesciences Corporation's earnings last quarter?
Edwards Lifesciences Corporation (NYSE:EW) posted its quarterly earnings data on Tuesday, April, 25th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.12. The company earned $883.50 million during the quarter, compared to analyst estimates of $776.51 million. Edwards Lifesciences Corporation had a return on equity of 25.80% and a net margin of 20.85%. Edwards Lifesciences Corporation's revenue was up 26.7% on a year-over-year basis. During the same period last year, the firm posted $0.71 EPS. View Edwards Lifesciences Corporation's Earnings History.
When will Edwards Lifesciences Corporation make its next earnings announcement?
What guidance has Edwards Lifesciences Corporation issued on next quarter's earnings?
Edwards Lifesciences Corporation issued an update on its FY17 earnings guidance on Tuesday, April, 25th. The company provided EPS guidance of $3.43-3.55 for the period, compared to the Thomson Reuters consensus estimate of $3.41. The company issued revenue guidance of $3.2-3.4 billion, compared to the consensus revenue estimate of $3.26 billion.Edwards Lifesciences Corporation also updated its Q2 guidance to $0.82-0.92 EPS.
Where is Edwards Lifesciences Corporation's stock going? Where will Edwards Lifesciences Corporation's stock price be in 2017?
22 brokers have issued 1 year price targets for Edwards Lifesciences Corporation's shares. Their predictions range from $14.00 to $150.00. On average, they expect Edwards Lifesciences Corporation's stock price to reach $114.95 in the next twelve months. View Analyst Ratings for Edwards Lifesciences Corporation.
What are analysts saying about Edwards Lifesciences Corporation stock?
Here are some recent quotes from research analysts about Edwards Lifesciences Corporation stock:
- 1. According to Zacks Investment Research, "Over the last three months, Edwards Lifesciences has outperformed the Zacks categorized Medical - Instruments industry. We believe several recent FDA approvals received by the company including its SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve have been boosting the investors’ confidence over the stock. Also, Edwards Lifesciences’ long-term growth strategy buoys optimism. The company’s focus on bulding its pipeline to strengthen its foothold across all its operating businesses is also encouraging. However, higher operating expenses continue to be a woe. The stock’s valuation also remains stretched on huge investments in the launch and promotion of products. Stiff competition, currency headwind and reimbursement issues are other challenges." (7/18/2017)
- 2. Cowen and Company analysts commented, "After hosting meetings with management last week, attending ACC, and reviewing early 1Q'17 MedMine hospital purchasing data, we remain bullish on Edwards' long term growth prospects. We are optimistic that additional layers of growth will be provided by low risk, asymptomatic and moderate AS indications along with EW's mitral and tricuspid platforms. Reiterate Outperform." (3/28/2017)
Who are some of Edwards Lifesciences Corporation's key competitors?
Some companies that are related to Edwards Lifesciences Corporation include Boston Scientific Corporation (BSX), Intuitive Surgical (ISRG), Koninklijke Philips N.V. (PHG), Illumina (ILMN), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), Hologic (HOLX), ResMed (RMD), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Accelerate Diagnostics (AXDX), Natus Medical Incorporated (BABY), Quidel Corporation (QDEL) and ABAXIS (ABAX).
Who are Edwards Lifesciences Corporation's key executives?
Edwards Lifesciences Corporation's management team includes the folowing people:
- Michael A. Mussallem, Chairman of the Board, Chief Executive Officer
- Scott B. Ullem, Chief Financial Officer, Corporate Vice President
- Donald E. Bobo Jr., Corporate Vice President - Heart Valve Therapy
- Catherine M. Szyman, Corporate Vice President- Critical Care
- Patrick Bruno Verguet, Corporate Vice President- Europe, Middle East and Africa
- Huimin Wang M.D., Corporate Vice President- Japan, Asia and Pacific
- Larry L. Wood, Corporate Vice President - Transcatheter Heart Valve Therapy
- Bernard J. Zovighian, Corporate Vice President -Surgical Heart Valve Therapy
- Kieran T. Gallahue, Independent Director
- Leslie Stone Heisz, Independent Director
Who owns Edwards Lifesciences Corporation stock?
Edwards Lifesciences Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include US Bancorp DE (0.11%), Rockefeller Financial Services Inc. (0.11%), National Pension Service (0.10%), Chevy Chase Trust Holdings Inc. (0.09%), Bank of Montreal Can (0.08%) and Factory Mutual Insurance Co. (0.06%). Company insiders that own Edwards Lifesciences Corporation stock include Barbara J Mcneil, Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Nick Demare, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Steven R Loranger and West Petroleum Corp East. View Institutional Ownership Trends for Edwards Lifesciences Corporation.
Who sold Edwards Lifesciences Corporation stock? Who is selling Edwards Lifesciences Corporation stock?
Edwards Lifesciences Corporation's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, First National Bank of Omaha, Fox Run Management L.L.C., OLD National Bancorp IN, Exxonmobil Investment Management Inc. TX, Bremer Trust National Association, Chevy Chase Trust Holdings Inc. and DnB Asset Management AS. Company insiders that have sold Edwards Lifesciences Corporation stock in the last year include Bernard J Zovighian, Donald E Bobo, Jr, Huimin Wang, John T Cardis, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers and Schack Wesley W Von. View Insider Buying and Selling for Edwards Lifesciences Corporation.
Who bought Edwards Lifesciences Corporation stock? Who is buying Edwards Lifesciences Corporation stock?
Edwards Lifesciences Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., National Pension Service, Mn Services Vermogensbeheer B.V., US Bancorp DE, Nisa Investment Advisors LLC, Aperio Group LLC, Rockefeller Financial Services Inc. and Chesley Taft & Associates LLC. Company insiders that have bought Edwards Lifesciences Corporation stock in the last two years include Catherine M Szyman, Dylan Sidoo, Kieran Gallahue, Nick Demare, Steven R Loranger and West Petroleum Corp East. View Insider Buying and Selling for Edwards Lifesciences Corporation.
How do I buy Edwards Lifesciences Corporation stock?
Shares of Edwards Lifesciences Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Edwards Lifesciences Corporation's stock price today?
One share of Edwards Lifesciences Corporation stock can currently be purchased for approximately $119.42.
MarketBeat Community Rating for Edwards Lifesciences Corporation (NYSE EW)MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Edwards Lifesciences Corporation (NYSE:EW) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 5 Hold Ratings, 15 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.73) |
| Consensus Price Target: | $114.95 (3.74% downside) |
Analysts' Ratings History for Edwards Lifesciences Corporation (NYSE:EW)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/17/2017 | SunTrust Banks, Inc. | Boost Price Target | Buy | $14.00 | Low |  |
| 6/30/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $115.00 | Low | |
| 6/28/2017 | Canaccord Genuity | Reiterated Rating | Buy | $150.00 | Low | |
| 5/30/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | | Low | |
| 5/30/2017 | Bank of America Corporation | Boost Price Target | Buy | $120.00 -> $140.00 | Low | |
| 5/16/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Conviction-Buy | $138.00 | Low | |
| 4/26/2017 | Stifel Nicolaus | Boost Price Target | Buy -> Buy | $114.00 -> $118.00 | High | |
| 3/28/2017 | Cowen and Company | Reiterated Rating | Outperform | $120.00 | Medium | |
| 3/27/2017 | Evercore ISI | Upgrade | In-Line -> Outperform | $98.50 -> $110.00 | Low | |
| 3/20/2017 | Northland Securities | Set Price Target | Buy | $105.00 | Low | |
| 2/8/2017 | Credit Suisse Group | Set Price Target | Buy | $120.00 | N/A | |
| 2/5/2017 | Deutsche Bank AG | Reiterated Rating | Hold | $100.00 | N/A | |
| 2/2/2017 | Leerink Swann | Downgrade | Outperform -> Market Perform | | N/A | |
| 2/2/2017 | BTIG Research | Downgrade | Buy -> Neutral | | N/A | |
| 1/3/2017 | Guggenheim | Upgrade | Neutral -> Buy | $120.00 | N/A | |
| 12/10/2016 | JMP Securities | Reiterated Rating | Equal Weight | $130.00 | N/A | |
| 12/10/2016 | Barclays PLC | Reiterated Rating | Equal Weight | $100.00 | N/A | |
| 12/1/2016 | J P Morgan Chase & Co | Set Price Target | Buy | $120.00 | N/A | |
| 9/11/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 8/19/2016 | Morgan Stanley | Reiterated Rating | Buy | $140.00 | N/A | |
| 7/27/2016 | Citigroup Inc. | Boost Price Target | Sell | $86.00 -> $94.00 | N/A | |
| 7/27/2016 | BMO Capital Markets | Reiterated Rating | Buy | $120.00 | N/A | |
| 6/21/2016 | William Blair | Reiterated Rating | Outperform | | N/A | |
| 6/21/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $123.00 | N/A | |
| 3/17/2016 | Nomura | Initiated Coverage | Buy | $101.00 | N/A | |
| 1/4/2016 | Sterne Agee CRT | Boost Price Target | Buy | $90.00 -> $92.00 | N/A | |
(Data available from 7/21/2015 forward)
Earnings History for Edwards Lifesciences Corporation (NYSE:EW)Earnings History by Quarter for Edwards Lifesciences Corporation (NYSE EW)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/24/2017 | | $0.88 | | | | | N/A | |
| 4/25/2017 | Q1 2017 | $0.82 | $0.94 | $776.51 million | $883.50 million | View | N/A | |
| 2/1/2017 | Q416 | $0.72 | $0.75 | $760.85 million | $767.70 million | View | N/A | |
| 10/25/2016 | Q316 | $0.68 | $0.68 | $749.14 million | $739.40 million | View | N/A | |
| 7/26/2016 | Q216 | $0.70 | $0.76 | $724.26 million | $759.30 million | View | N/A | |
| 4/26/2016 | Q116 | $0.66 | $0.71 | $664.53 million | $697.30 million | View | N/A | |
| 2/2/2016 | Q415 | $0.62 | $0.63 | $647.44 million | $671.10 million | View | N/A | |
| 10/26/2015 | Q315 | $0.98 | $1.07 | $598.29 million | $615.00 million | View | N/A | |
| 7/28/2015 | Q215 | $1.05 | $1.13 | $604.97 million | $616.80 million | View | N/A | |
| 4/23/2015 | Q115 | $1.04 | $1.12 | $585.16 million | $590.30 million | View | N/A | |
| 2/3/2015 | Q414 | $0.95 | $1.06 | $610.50 million | $618.00 million | View | Listen | |
| 10/23/2014 | Q314 | $0.72 | $0.80 | $546.10 million | $607.40 million | View | Listen | |
| 7/29/2014 | Q214 | $0.77 | $0.88 | $545.10 million | $547.00 million | View | Listen | |
| 4/24/2014 | Q114 | $0.69 | $0.76 | $523.10 million | $522.40 million | View | Listen | |
| 2/3/2014 | Q413 | $0.82 | $0.91 | $533.82 million | $536.00 million | View | N/A | |
| 10/28/2013 | Q313 | $0.66 | $0.68 | $490.96 million | $496.00 million | View | N/A | |
| 7/25/2013 | Q2 2013 | $0.76 | $0.82 | $514.59 million | $517.20 million | View | N/A | |
| 4/23/2013 | Q1 2013 | $0.76 | $0.72 | $518.69 million | $496.70 million | View | N/A | |
| 2/4/2013 | Q4 2012 | $0.77 | $0.77 | $499.46 million | $510.50 million | View | N/A | |
| 10/19/2012 | | $0.56 | $0.58 | | | View | N/A | |
| 7/24/2012 | | $0.66 | $0.67 | | | View | N/A | |
| 2/2/2012 | | $0.59 | $0.62 | | | View | N/A | |
| 10/19/2011 | | $0.39 | $0.38 | | | View | N/A | |
| 7/21/2011 | | $0.50 | $0.49 | | | View | N/A | |
| 4/20/2011 | | $0.42 | $0.51 | | | View | N/A | |
| 2/2/2011 | | $0.53 | $0.55 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Edwards Lifesciences Corporation (NYSE:EW)2017 EPS Consensus Estimate: $3.40
2018 EPS Consensus Estimate: $3.99
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | $0.82 | $0.85 | $0.84 |
| Q2 2017 | 4 | $0.87 | $0.89 | $0.88 |
| Q3 2017 | 4 | $0.78 | $0.84 | $0.81 |
| Q4 2017 | 4 | $0.86 | $0.89 | $0.88 |
| Q1 2018 | 3 | $0.95 | $1.09 | $1.01 |
| Q2 2018 | 3 | $0.98 | $1.04 | $1.00 |
| Q3 2018 | 3 | $0.92 | $0.98 | $0.94 |
| Q4 2018 | 3 | $1.01 | $1.05 | $1.03 |
(Data provided by Zacks Investment Research)
Dividend History for Edwards Lifesciences Corporation (NYSE:EW)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Edwards Lifesciences Corporation (NYSE:EW)Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 83.62%
Insider Trades by Quarter for Edwards Lifesciences Corporation (NYSE:EW)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/29/2017 | Donald E. Bobo, Jr. | VP | Sell | 5,600 | $117.15 | $656,040.00 | |
| 6/7/2017 | Michael A. Mussallem | CEO | Sell | 32,900 | $118.05 | $3,883,845.00 | |
| 5/31/2017 | Patrick B. Verguet | VP | Sell | 10,000 | $114.88 | $1,148,800.00 | |
| 5/19/2017 | Dylan Sidoo | Director | Buy | 25,000 | $0.11 | $2,750.00 | |
| 5/19/2017 | Patrick B. Verguet | VP | Sell | 22,631 | $113.16 | $2,560,923.96 | |
| 5/15/2017 | Patrick B. Verguet | VP | Sell | 11,500 | $111.64 | $1,283,860.00 | |
| 5/8/2017 | Donald E. Bobo, Jr. | VP | Sell | 19,100 | $110.34 | $2,107,494.00 | |
| 5/4/2017 | Donald E. Bobo, Jr. | VP | Sell | 34,120 | $109.98 | $3,752,517.60 | |
| 5/3/2017 | Michael A. Mussallem | CEO | Sell | 49,100 | $109.71 | $5,386,761.00 | |
| 4/28/2017 | Michael A. Mussallem | CEO | Sell | 49,100 | $109.78 | $5,390,198.00 | |
| 4/27/2017 | Bernard J. Zovighian | VP | Sell | 18,050 | $109.21 | $1,971,240.50 | |
| 4/5/2017 | Donald E. Bobo, Jr. | VP | Sell | 13,720 | $93.58 | $1,283,917.60 | |
| 3/30/2017 | Patrick B. Verguet | VP | Sell | 24,000 | $93.90 | $2,253,600.00 | |
| 3/6/2017 | Donald E. Bobo, Jr. | VP | Sell | 13,720 | $90.01 | $1,234,937.20 | |
| 2/16/2017 | Michael A. Mussallem | CEO | Sell | 49,100 | $89.63 | $4,400,833.00 | |
| 2/3/2017 | Kieran Gallahue | Director | Buy | 3,000 | $90.10 | $270,300.00 | |
| 1/13/2017 | Michael A. Mussallem | CEO | Sell | 49,100 | $97.08 | $4,766,628.00 | |
| 1/12/2017 | Donald E. Bobo, Jr. | VP | Sell | 13,720 | $97.47 | $1,337,288.40 | |
| 1/12/2017 | Dylan Sidoo | Director | Buy | 30,000 | $0.13 | $3,900.00 | |
| 1/11/2017 | Dylan Sidoo | Director | Buy | 20,000 | $0.13 | $2,600.00 | |
| 12/19/2016 | Michael A. Mussallem | CEO | Sell | 49,100 | $91.96 | $4,515,236.00 | |
| 12/5/2016 | Huimin Wang | VP | Sell | 13,650 | $83.53 | $1,140,184.50 | |
| 12/1/2016 | Larry L. Wood | VP | Sell | 13,258 | $81.85 | $1,085,167.30 | |
| 11/30/2016 | Catherine M. Szyman | VP | Buy | 12,870 | $83.43 | $1,073,744.10 | |
| 11/29/2016 | Kieran Gallahue | Director | Buy | 3,000 | $84.63 | $253,890.00 | |
| 11/22/2016 | Michael A. Mussallem | CEO | Sell | 49,100 | $84.67 | $4,157,297.00 | |
| 11/7/2016 | Huimin Wang | VP | Sell | 13,650 | $91.29 | $1,246,108.50 | |
| 11/2/2016 | Donald E. Bobo, Jr. | VP | Sell | 15,000 | $90.13 | $1,351,950.00 | |
| 11/1/2016 | Larry L. Wood | VP | Sell | 13,257 | $93.27 | $1,236,480.39 | |
| 10/27/2016 | Michael A. Mussallem | CEO | Sell | 49,100 | $92.77 | $4,555,007.00 | |
| 10/5/2016 | Huimin Wang | VP | Sell | 13,650 | $120.04 | $1,638,546.00 | |
| 10/3/2016 | Larry L. Wood | VP | Sell | 13,257 | $119.27 | $1,581,162.39 | |
| 9/6/2016 | Huimin Wang | VP | Sell | 13,650 | $115.72 | $1,579,578.00 | |
| 9/2/2016 | Donald E. Bobo, Jr. | VP | Sell | 18,000 | $115.78 | $2,084,040.00 | |
| 8/26/2016 | Patrick B. Verguet | VP | Sell | 5,000 | $114.88 | $574,400.00 | |
| 8/24/2016 | Patrick B. Verguet | VP | Sell | 5,000 | $116.81 | $584,050.00 | |
| 8/23/2016 | Patrick B. Verguet | VP | Sell | 10,092 | $117.53 | $1,186,112.76 | |
| 8/11/2016 | Michael A. Mussallem | CEO | Sell | 49,100 | $114.01 | $5,597,891.00 | |
| 8/10/2016 | John T. Cardis | Director | Sell | 5,000 | $113.21 | $566,050.00 | |
| 8/9/2016 | Patrick B. Verguet | VP | Sell | 10,000 | $113.48 | $1,134,800.00 | |
| 8/5/2016 | Huimin Wang | VP | Sell | 13,650 | $113.03 | $1,542,859.50 | |
| 8/1/2016 | Larry L. Wood | VP | Sell | 13,257 | $114.24 | $1,514,479.68 | |
| 8/1/2016 | Schack Wesley W. Von | Director | Sell | 6,000 | $113.98 | $683,880.00 | |
| 7/29/2016 | Robert W.A. Sellers | VP | Sell | 10,000 | $114.33 | $1,143,300.00 | |
| 7/28/2016 | Michael A. Mussallem | CEO | Sell | 49,100 | $113.31 | $5,563,521.00 | |
| 7/5/2016 | Huimin Wang | VP | Sell | 13,650 | $98.44 | $1,343,706.00 | |
| 7/1/2016 | Larry L. Wood | VP | Sell | 13,257 | $98.79 | $1,309,659.03 | |
| 6/8/2016 | Michael A Mussallem | CEO | Sell | 49,100 | $102.75 | $5,045,025.00 | |
| 6/6/2016 | Huimin Wang | VP | Sell | 13,650 | $101.34 | $1,383,291.00 | |
| 6/3/2016 | Larry L Wood | VP | Sell | 13,257 | $101.38 | $1,343,994.66 | |
| 5/31/2016 | Donald E Bobo Jr | VP | Sell | 18,000 | $99.04 | $1,782,720.00 | |
| 5/24/2016 | Steven R Loranger | Director | Buy | 5,000 | $101.07 | $505,350.00 | |
| 5/18/2016 | Patrick B Verguet | VP | Sell | 13,000 | $102.75 | $1,335,750.00 | |
| 5/17/2016 | Patrick B Verguet | VP | Sell | 5,000 | $105.00 | $525,000.00 | |
| 5/16/2016 | Patrick B Verguet | VP | Sell | 3,000 | $104.62 | $313,860.00 | |
| 5/5/2016 | Huimin Wang | VP | Sell | 13,650 | $103.36 | $1,410,864.00 | |
| 5/5/2016 | Michael A Mussallem | CEO | Sell | 59,000 | $104.12 | $6,143,080.00 | |
| 5/2/2016 | Patrick B Verguet | VP | Sell | 7,000 | $106.86 | $748,020.00 | |
| 4/29/2016 | Michael A Mussallem | CEO | Sell | 59,000 | $106.13 | $6,261,670.00 | |
| 4/5/2016 | Huimin Wang | VP | Sell | 13,650 | $103.97 | $1,419,190.50 | |
| 3/17/2016 | Michael A Mussallem | CEO | Sell | 59,000 | $84.39 | $4,979,010.00 | |
| 3/7/2016 | Huimin Wang | VP | Sell | 13,650 | $87.17 | $1,189,870.50 | |
| 2/18/2016 | Michael A. Mussallem | CEO | Sell | 59,000 | $86.94 | $5,129,460.00 | |
| 2/18/2016 | Patrick B. Verguet | VP | Sell | 5,000 | $87.00 | $435,000.00 | |
| 2/16/2016 | Patrick B. Verguet | VP | Sell | 8,000 | $81.58 | $652,640.00 | |
| 2/5/2016 | Huimin Wang | VP | Sell | 13,650 | $83.46 | $1,139,229.00 | |
| 2/4/2016 | Barbara J. Mcneil | Director | Sell | 4,000 | $83.29 | $333,160.00 | |
| 1/21/2016 | Patrick B. Verguet | VP | Sell | 8,000 | $77.00 | $616,000.00 | |
| 1/6/2016 | Nick Demare | Director | Buy | 15,000 | $0.08 | $1,200.00 | |
| 1/5/2016 | Huimin Wang | VP | Sell | 13,650 | $78.50 | $1,071,525.00 | |
| 1/5/2016 | Michael A. Mussallem | CEO | Sell | 59,000 | $79.82 | $4,709,380.00 | |
| 12/17/2015 | Michael A. Mussallem | CEO | Sell | 59,000 | $81.85 | $4,829,150.00 | |
| 12/15/2015 | Patrick B. Verguet | VP | Sell | 8,000 | $80.87 | $646,960.00 | |
| 12/4/2015 | Huimin Wang | VP | Sell | 6,880 | $157.96 | $1,086,764.80 | |
| 11/27/2015 | Patrick B. Verguet | VP | Sell | 7,500 | $164.50 | $1,233,750.00 | |
| 11/23/2015 | Robert W.A. Sellers | VP | Sell | 19,200 | $157.13 | $3,016,896.00 | |
| 11/17/2015 | Patrick B. Verguet | VP | Sell | 4,000 | $154.50 | $618,000.00 | |
| 11/5/2015 | Huimin Wang | VP | Sell | 6,920 | $156.01 | $1,079,589.20 | |
| 11/3/2015 | Patrick B. Verguet | VP | Sell | 4,338 | $158.48 | $687,486.24 | |
| 10/30/2015 | Patrick B. Verguet | VP | Sell | 22,000 | $155.09 | $3,411,980.00 | |
| 10/29/2015 | Michael A Mussallem | CEO | Sell | 29,500 | $154.59 | $4,560,405.00 | |
| 10/5/2015 | Huimin Wang | VP | Sell | 6,920 | $154.30 | $1,067,756.00 | |
| 10/2/2015 | Patrick B. Verguet | VP | Sell | 4,000 | $154.00 | $616,000.00 | |
| 10/1/2015 | Larry L. Wood | VP | Sell | 7,680 | $141.52 | $1,086,873.60 | |
| 9/21/2015 | Michael A. Mussallem | CEO | Sell | 29,500 | $142.49 | $4,203,455.00 | |
| 9/4/2015 | Huimin Wang | VP | Sell | 6,920 | $135.19 | $935,514.80 | |
| 9/1/2015 | Larry L. Wood | VP | Sell | 7,680 | $137.50 | $1,056,000.00 | |
| 8/24/2015 | Michael A. Mussallem | CEO | Sell | 29,500 | $135.25 | $3,989,875.00 | |
| 8/13/2015 | West Petroleum Corp. East | Insider | Buy | 25,000 | $0.12 | $2,875.00 | |
| 7/6/2015 | Huimin Wang | VP | Sell | 6,920 | $143.95 | $996,134.00 | |
| 7/1/2015 | Larry L Wood | VP | Sell | 7,680 | $143.51 | $1,102,156.80 | |
| 6/24/2015 | Michael A Mussallem | CEO | Sell | 29,500 | $143.71 | $4,239,445.00 | |
| 6/5/2015 | Huimin Wang | VP | Sell | 6,920 | $131.39 | $909,218.80 | |
| 6/1/2015 | Larry L Wood | VP | Sell | 7,680 | $130.47 | $1,002,009.60 | |
| 5/29/2015 | Patrick B Verguet | VP | Sell | 9,662 | $131.18 | $1,267,461.16 | |
| 5/21/2015 | Barbara J Mcneil | Director | Sell | 2,000 | $132.59 | $265,180.00 | |
| 5/19/2015 | Robert Marc Bustin | Director | Sell | 10,000 | $0.18 | $1,750.00 | |
| 5/1/2015 | Larry L Wood | VP | Sell | 7,680 | $127.12 | $976,281.60 | |
| 4/30/2015 | Michael A Mussallem | CEO | Sell | 29,500 | $128.99 | $3,805,205.00 | |
| 4/6/2015 | Huimin Wang | VP | Sell | 6,920 | $140.24 | $970,460.80 | |
| 4/1/2015 | Larry L Wood | VP | Sell | 7,680 | $142.06 | $1,091,020.80 | |
| 3/31/2015 | Robert Marc Bustin | Director | Buy | 15,000 | $0.15 | $2,250.00 | |
| 3/26/2015 | Michael A Mussallem | CEO | Sell | 29,500 | $140.10 | $4,132,950.00 | |
| 3/2/2015 | Larry L Wood | VP | Sell | 7,680 | $132.62 | $1,018,521.60 | |
| 2/6/2015 | Huimin Wang | VP | Sell | 6,920 | $134.79 | $932,746.80 | |
| 1/5/2015 | Huimin Wang | VP | Sell | 6,920 | $126.60 | $876,072.00 | |
| 1/5/2015 | Michael A Mussallem | CEO | Sell | 29,500 | $128.20 | $3,781,900.00 | |
| 12/22/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $133.01 | $3,923,795.00 | |
| 11/24/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $124.25 | $3,665,375.00 | |
| 11/13/2014 | Robert W.A. Sellers | VP | Sell | 3,400 | $124.27 | $422,518.00 | |
| 11/10/2014 | Patrick B Verguet | VP | Sell | 5,000 | $123.70 | $618,500.00 | |
| 11/7/2014 | Schack Wesley W Von | Director | Sell | 3,655 | $123.00 | $449,565.00 | |
| 11/5/2014 | Huimin Wang | VP | Sell | 5,600 | $120.26 | $673,456.00 | |
| 10/28/2014 | Barbara J Mcneil | Director | Sell | 1,000 | $117.94 | $117,940.00 | |
| 10/28/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $117.06 | $3,453,270.00 | |
| 10/28/2014 | Patrick B Verguet | VP | Sell | 15,000 | $117.33 | $1,759,950.00 | |
| 10/28/2014 | West Petroleum Corp. East | Insider | Buy | 15,000 | $0.12 | $1,800.00 | |
| 10/27/2014 | Patrick B Verguet | VP | Sell | 10,000 | $117.00 | $1,170,000.00 | |
| 10/27/2014 | West Petroleum Corp. East | Insider | Buy | 20,000 | $0.13 | $2,600.00 | |
| 10/24/2014 | Donald E Bobo Jr | VP | Sell | 30,000 | $114.25 | $3,427,500.00 | |
| 10/24/2014 | West Petroleum Corp. East | Insider | Buy | 35,000 | $0.14 | $4,725.00 | |
| 10/23/2014 | West Petroleum Corp. East | Insider | Buy | 40,000 | $0.15 | $5,800.00 | |
| 10/6/2014 | Huimin Wang | VP | Sell | 5,600 | $107.00 | $599,200.00 | |
| 10/3/2014 | Donald E Bobo Jr | VP | Sell | 25,000 | $105.00 | $2,625,000.00 | |
| 9/29/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $102.71 | $3,029,945.00 | |
| 9/10/2014 | Donald E Bobo Jr | VP | Sell | 25,000 | $100.00 | $2,500,000.00 | |
| 9/5/2014 | Huimin Wang | VP | Sell | 5,600 | $98.29 | $550,424.00 | |
| 8/27/2014 | Carlyn D Solomon | VP | Sell | 85,200 | $97.85 | $8,336,820.00 | |
| 8/27/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $98.14 | $2,895,130.00 | |
| 8/18/2014 | John T Cardis | Director | Sell | 6,000 | $97.92 | $587,520.00 | |
| 8/18/2014 | Larry L Wood | VP | Sell | 63,752 | $97.85 | $6,238,133.20 | |
| 8/13/2014 | Patrick B Verguet | VP | Sell | 7,800 | $95.50 | $744,900.00 | |
| 8/5/2014 | Patrick B Verguet | VP | Sell | 15,000 | $94.05 | $1,410,750.00 | |
| 8/4/2014 | Patrick B Verguet | VP | Sell | 5,000 | $93.00 | $465,000.00 | |
| 8/1/2014 | Patrick B Verguet | VP | Sell | 5,000 | $92.00 | $460,000.00 | |
| 7/31/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $91.98 | $2,713,410.00 | |
| 7/31/2014 | Robert Alexander Ingram | Director | Sell | 12,500 | $90.26 | $1,128,250.00 | |
| 7/31/2014 | Robert W.A. Sellers | VP | Sell | 8,850 | $91.47 | $809,509.50 | |
| 7/30/2014 | Donald E Bobo Jr | VP | Sell | 23,270 | $92.00 | $2,140,840.00 | |
| 7/7/2014 | Huimin Wang | VP | Sell | 5,600 | $87.79 | $491,624.00 | |
| 6/27/2014 | Donald E Bobo Jr | VP | Sell | 25,000 | $87.00 | $2,175,000.00 | |
| 6/24/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $85.38 | $2,518,710.00 | |
| 6/5/2014 | Huimin Wang | VP | Sell | 5,600 | $80.73 | $452,088.00 | |
| 5/30/2014 | Barbara J Mcneil | Director | Sell | 1,200 | $81.20 | $97,440.00 | |
| 5/28/2014 | Michael A Mussallem | CEO | Sell | 29,500 | $79.33 | $2,340,235.00 | |
| 4/14/2014 | Donald Bobo, Jr. | VP | Sell | 25,000 | $82.00 | $2,050,000.00 | |
| 4/10/2014 | Michael Mussallem | CEO | Sell | 29,500 | $74.71 | $2,203,945.00 | |
| 4/7/2014 | Huimin Wang | VP | Sell | 5,600 | $74.03 | $414,568.00 | |
| 3/24/2014 | Michael Bowlin | Director | Sell | 1,093 | $72.33 | $79,056.69 | |
| 3/6/2014 | Robert W.A. Sellers | VP | Sell | 1,650 | $72.88 | $120,252.00 | |
| 2/6/2014 | Michael Mussallem | CEO | Sell | 29,500 | $66.92 | $1,974,140.00 | |
| 1/27/2014 | Michael Bowlin | Director | Sell | 1,092 | $68.65 | $74,965.80 | |
| 1/9/2014 | Michael Mussallem | CEO | Sell | 29,500 | $67.04 | $1,977,680.00 | |
| 1/6/2014 | Huimin Wang | VP | Sell | 5,600 | $67.14 | $375,984.00 | |
| 12/11/2013 | Patrick Verguet | VP | Sell | 10,000 | $62.34 | $623,400.00 | |
| 12/5/2013 | Huimin Wang | VP | Sell | 4,650 | $64.65 | $300,622.50 | |
| 12/4/2013 | Michael Mussallem | CEO | Sell | 29,500 | $64.90 | $1,914,550.00 | |
| 10/9/2013 | Michael Mussallem | CEO | Sell | 29,500 | $72.63 | $2,142,585.00 | |
| 10/4/2013 | Huimin Wang | VP | Sell | 4,850 | $72.19 | $350,121.50 | |
| 9/12/2013 | Michael Mussallem | CEO | Sell | 29,500 | $71.82 | $2,118,690.00 | |
| 9/5/2013 | Huimin Wang | VP | Sell | 4,850 | $71.24 | $345,514.00 | |
| 8/8/2013 | Michael Mussallem | CEO | Sell | 29,500 | $72.28 | $2,132,260.00 | |
| 8/5/2013 | Huimin Wang | VP | Sell | 4,850 | $72.30 | $350,655.00 | |
| 8/1/2013 | Patrick Verguet | VP | Sell | 20,000 | $73.15 | $1,463,000.00 | |
| 7/10/2013 | Michael A Mussallem | CEO | Sell | 29,500 | $65.60 | $1,935,200.00 | |
| 7/5/2013 | Huimin Wang | VP | Sell | 4,850 | $65.69 | $318,596.50 | |
| 6/6/2013 | Michael A Mussallem | CEO | Sell | 29,500 | $66.25 | $1,954,375.00 | |
| 6/5/2013 | Huimin Wang | VP | Sell | 4,850 | $65.11 | $315,783.50 | |
| 5/13/2013 | Paul C Redmond | VP | Sell | 5,000 | $67.35 | $336,750.00 | |
| 5/8/2013 | Michael A Mussallem | CEO | Sell | 29,200 | $64.24 | $1,875,808.00 | |
| 5/7/2013 | Thomas M Abate | CFO | Sell | 15,000 | $63.75 | $956,250.00 | |
| 5/3/2013 | Schack Wesley W Von | Director | Buy | 1,000 | $64.00 | $64,000.00 | |
| 5/1/2013 | David E I Pyott | Director | Buy | 3,000 | $62.95 | $188,850.00 | |
| 5/1/2013 | John H Kehl Jr | VP | Sell | 12,500 | $62.72 | $784,000.00 | |
| 4/26/2013 | Schack Wesley W Von | Director | Buy | 2,000 | $64.95 | $129,900.00 | |
| 4/10/2013 | Michael A Mussallem | CEO | Sell | 35,000 | $83.37 | $2,917,950.00 | |
| 3/13/2013 | John H Kehl Jr | VP | Sell | 12,500 | $87.75 | $1,096,875.00 | |
| 10/5/2012 | Huimin Wang | VP | Sell | 6,250 | $109.88 | $686,750.00 | |
| 10/4/2012 | Donald E Bobo Jr | VP | Sell | 11,530 | $110.14 | $1,269,914.20 | |
| 8/9/2012 | Michael A Mussallem | CEO | Sell | 35,000 | $98.69 | $3,454,150.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Edwards Lifesciences Corporation (NYSE:EW)
Latest Headlines for Edwards Lifesciences Corporation (NYSE:EW)
| Source: |
|
| Date | Headline |
|---|
 | Edwards Lifesciences: Cramer's Top Takeaways
finance.yahoo.com - July 20 at 12:15 AM |
| Edwards Lifesciences (EW) Q2 Earnings: A Surprise in Store?
finance.yahoo.com - July 19 at 7:11 PM |
| Cramer Remix: Snap is the No. 1 reason to own Facebook
finance.yahoo.com - July 19 at 7:11 PM |
 | Q2 2018 EPS Estimates for Edwards Lifesciences Corporation Reduced by Analyst (NYSE:EW)
www.americanbankingnews.com - July 19 at 1:48 PM |
| Edwards Lifesciences Corporation to Post Q3 2017 Earnings of $0.83 Per Share, SunTrust Banks Forecasts (EW)
www.americanbankingnews.com - July 18 at 9:54 AM |
 | Haemonetics Plasma Arm Advances, Blood Center Sluggish - Nasdaq
www.nasdaq.com - July 17 at 7:27 PM |
| Why Is It the Perfect Time to Buy Thermo Fisher (TMO) Stock?
finance.yahoo.com - July 17 at 7:27 PM |
| Haemonetics Plasma Arm Advances, Blood Center Sluggish
finance.yahoo.com - July 17 at 7:27 PM |
| Edwards Lifesciences Corporation (EW) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 17 at 12:52 PM |
| Edwards Lifesciences Corporation (EW) Price Target Raised to $14.00 at SunTrust Banks, Inc.
www.americanbankingnews.com - July 17 at 9:58 AM |
| Edwards Lifesciences Corporation (NYSE:EW) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - July 17 at 8:53 AM |
| Edwards Lifesciences Corporation (EW) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 14 at 8:20 PM |
| Abbott Partners Bigfoot Biomedical to Expand in Diabetics - Nasdaq
www.nasdaq.com - July 14 at 5:01 PM |
| DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando - Nasdaq
www.nasdaq.com - July 14 at 5:01 PM |
| Avantor to Acquire VWR, Consolidation Promises Global Gains
finance.yahoo.com - July 14 at 5:01 PM |
| $836.05 Million in Sales Expected for Edwards Lifesciences Corporation (EW) This Quarter
www.americanbankingnews.com - July 13 at 1:20 PM |
| PAREXEL (PRXL) Gets CEO Cancer Gold Standard Accreditation
finance.yahoo.com - July 13 at 5:24 AM |
| Here's Why You Should Add ResMed to Your Portfolio Now
finance.yahoo.com - July 13 at 5:24 AM |
| Masimo (MASI) Rainbow Super DCI-mini Sensor Now CE Marked ... - Nasdaq
www.nasdaq.com - July 12 at 7:12 PM |
| Edwards Lifesciences To Host Earnings Conference Call On July 26, 2017
finance.yahoo.com - July 12 at 7:12 PM |
| Neogen Introduces Test for Listeria in Environmental Samples
finance.yahoo.com - July 12 at 12:38 AM |
| Buy 5 Top Profitable Stocks for Remarkable Returns - Nasdaq
www.nasdaq.com - July 11 at 7:36 PM |
| Analysts Anticipate Edwards Lifesciences Corporation (NYSE:EW) Will Post Earnings of $0.88 Per Share
www.americanbankingnews.com - July 11 at 9:38 AM |
| Edwards Lifesciences Corporation (NYSE:EW) PT Lowered to $5.00
www.americanbankingnews.com - July 11 at 7:12 AM |
| Medtronic Valve Replacement Approval: Good News, But The Stock Still Fell
finance.yahoo.com - July 10 at 6:22 PM |
| Zacks Industry Outlook Highlights: Varian Medical Systems, Inogen, Edwards Lifesciences, Orthofix International and INSYS Therapeutics
finance.yahoo.com - July 8 at 10:38 AM |
 | Edwards Lifesciences (EW) Granted FDA Approval for INSPIRIS RESILIA Aortic Valve - StreetInsider.com
www.streetinsider.com - July 7 at 5:49 AM |
| Edwards Lifesciences' INSPIRIS RESILIA Valve Wins FDA Nod
www.nasdaq.com - July 6 at 7:44 PM |
| Edwards Lifesciences' INSPIRIS RESILIA Valve Wins FDA Nod
finance.yahoo.com - July 6 at 7:44 PM |
| Edwards Lifesciences (EW) Granted FDA Approval for INSPIRIS RESILIA Aortic Valve
www.streetinsider.com - July 6 at 1:47 AM |
| Edwards' INSPIRIS RESILIA Valve Receives FDA Approval
finance.yahoo.com - July 5 at 7:09 PM |
| Edwards Lifesciences Corporation (EW) VP Sells $656,040.00 in Stock
www.americanbankingnews.com - July 3 at 7:29 PM |
| Jefferies Group LLC Reaffirms Buy Rating for Edwards Lifesciences Corporation (EW)
www.americanbankingnews.com - June 30 at 8:02 AM |
| Canaccord Genuity Reaffirms "Buy" Rating for Edwards Lifesciences Corporation (EW)
www.americanbankingnews.com - June 28 at 9:16 PM |
| Edwards Lifesciences Gets ‘Buy’ Ratings from 77% of Analysts
finance.yahoo.com - June 26 at 6:07 PM |
| Edwards Lifesciences Corporation (EW) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - June 24 at 1:12 PM |
| Why Investors Should Buy Edwards Lifesciences (EW) Right Now - Nasdaq
www.nasdaq.com - June 23 at 5:41 PM |
| Heart Valve Maker Trying To Pump Stock Past Buy Zone
finance.yahoo.com - June 20 at 5:46 PM |
| Edwards Lifesciences Corporation (EW) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 19 at 8:50 PM |
| Edwards Lifesciences Corporation (EW) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - June 18 at 11:26 AM |
| Brokerages Expect Edwards Lifesciences Corporation (EW) Will Post Quarterly Sales of $835.56 Million
www.americanbankingnews.com - June 17 at 11:44 AM |
| Neovasc (NVCN) Says German Court Partially Found in Favour of ... - StreetInsider.com
www.streetinsider.com - June 16 at 3:52 PM |
| $0.88 Earnings Per Share Expected for Edwards Lifesciences Corporation (EW) This Quarter
www.americanbankingnews.com - June 15 at 8:40 AM |
| Michael A. Mussallem Sells 32,900 Shares of Edwards Lifesciences Corp (EW) Stock
www.americanbankingnews.com - June 8 at 7:12 PM |
| Zacks Investment Research Lowers Edwards Lifesciences Corp (EW) to Hold
www.americanbankingnews.com - June 8 at 1:36 PM |
| Edwards Lifesciences Corp (EW) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - June 7 at 9:44 AM |
| Edwards Lifesciences (EW) SAPIEN 3 THV Gets FDA Approval - Nasdaq
www.nasdaq.com - June 6 at 5:30 PM |
| Edwards Lifesciences To Present At Goldman Sachs 38th Annual Global Healthcare Conference
finance.yahoo.com - June 6 at 5:30 PM |
| Edwards Lifesciences (EW) Announces SAPIEN 3 Valve Receives FDA Approval For Aortic, Mitral Valve-In-Valve Procedures
www.streetinsider.com - June 5 at 10:13 PM |
| Edwards SAPIEN 3 Valve Receives FDA Approval For Aortic, Mitral Valve-In-Valve Procedures
finance.yahoo.com - June 5 at 5:12 PM |
Edwards Lifesciences Corporation (EW) Chart for Friday, July, 21, 2017
